pdufa.bio

LEQEMBI IQLIK (lecanemab-irmb)

Page updated ·next FDA decision on the calendar ·Data as of Nov 12, 2026 2:24 AM ET

The FDA approved LEQEMBI IQLIK (lecanemab-irmb) on Jul 13, 2026. 2 FDA decisions on record below. Every date links its source.

BIIB catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 2 catalyst events for this program: 0 upcoming and 2 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

FDA decision · Aug 29, 2025 ✓ ApprovedBIIBFDA decision · Jul 13, 2026 ✓ ApprovedBIIB

Specialist biotech funds holding BIIB, 13F for the quarter ended June 30, 2026

FundSharesValue at quarter endFiling
Perceptive Advisors276,173$59.7 millionfiled August 14, 2026
OrbiMed Advisors61,600$13.3 millionfiled August 14, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is LEQEMBI IQLIK (lecanemab-irmb)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for LEQEMBI IQLIK (lecanemab-irmb); 2 FDA decisions are on record below.

What happened at LEQEMBI IQLIK (lecanemab-irmb)'s most recent FDA decision?

On Jul 13, 2026 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has LEQEMBI IQLIK (lecanemab-irmb) been approved by the FDA?

Yes. The FDA approved an application for LEQEMBI IQLIK (lecanemab-irmb) on Jul 13, 2026; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.